These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8831345)

  • 1. Torsade de pointes.
    Campens D
    Anesth Analg; 1996 Oct; 83(4):887. PubMed ID: 8831345
    [No Abstract]   [Full Text] [Related]  

  • 2. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC; Morton BC; Green MS; Tang AS
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone.
    Takahara A; Nakamura Y; Sugiyama A
    Eur J Pharmacol; 2008 Oct; 596(1-3):127-31. PubMed ID: 18786527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Conversion to sinus rhythm].
    Brunckhorst CB
    Praxis (Bern 1994); 2006 Feb; 95(7):247-8. PubMed ID: 16524116
    [No Abstract]   [Full Text] [Related]  

  • 5. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
    Makkar RR; Fromm BS; Steinman RT; Meissner MD; Lehmann MH
    JAMA; 1993 Dec; 270(21):2590-7. PubMed ID: 8230644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Amiodarone-induced torsade de pointes--five case reports].
    Kukla P; Słowiak-Lewińska T
    Kardiol Pol; 2004 Apr; 60(4):365-70; discussion 371. PubMed ID: 15226788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
    Yasuda M; Nakazato Y; Sasaki A; Kawano Y; Nakazato K; Tokano T; Daida H
    Circ J; 2006 Jun; 70(6):662-6. PubMed ID: 16723784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia.
    Ohki R; Takahashi M; Mizuno O; Fujikawa H; Mitsuhashi T; Katsuki T; Ikeda U; Shimada K
    Pacing Clin Electrophysiol; 2001 Jan; 24(1):119-21. PubMed ID: 11227957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amiodarone-induced torsade de pointes in a patient with wolff-Parkinson-White syndrome.
    Badshah A; Mirza B; Janjua M; Nair R; Steinman RT; Cotant JF
    Hellenic J Cardiol; 2009; 50(3):224-6. PubMed ID: 19465366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amiodarone-associated macroscopic T-wave alternans and torsade de pointes unmasking the inherited long QT syndrome.
    Wegener FT; Ehrlich JR; Hohnloser SH
    Europace; 2008 Jan; 10(1):112-3. PubMed ID: 18006559
    [No Abstract]   [Full Text] [Related]  

  • 13. Flecainide-associated bradycardia-dependent torsade de pointes: another potential mechanism of proarrhythmia.
    Kim HS; Pak HN; Park JS; Kim SS
    Pacing Clin Electrophysiol; 2013 Mar; 36(3):e84-6. PubMed ID: 21029131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced torsade de pointes.
    Trohman RG; Sahu J
    Circulation; 1999 Apr; 99(16):E7. PubMed ID: 10217665
    [No Abstract]   [Full Text] [Related]  

  • 15. [Torsade de pointes].
    Ebihara Y; Nakamura Y
    Nihon Rinsho; 1991 Nov; 49(11):2578-83. PubMed ID: 1685194
    [No Abstract]   [Full Text] [Related]  

  • 16. ECG Diagnosis: Ibutilide-induced Torsade de Pointes.
    Le DD; Levis JT; Lugovskaya N; Vinson DR
    Perm J; 2019; 23():. PubMed ID: 30939273
    [No Abstract]   [Full Text] [Related]  

  • 17. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias.
    Van Opstal JM; Leunissen JD; Wellens HJ; Vos MA
    Eur J Pharmacol; 2001 Jan; 412(1):67-76. PubMed ID: 11166738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of bepridil: from review of the European data.
    Coumel P
    Am J Cardiol; 1992 Apr; 69(11):75D-78D. PubMed ID: 1553894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of sick sinus syndrome that developed torsades de pointes, pacing failure and sensing failure during administration of bepridil.
    Ohsawa M; Tanaka F; Kunugita F; Saito H; Nakamura M; Shiroto T; Hotta K; Chiba N; Hiramori K
    Jpn Heart J; 2003 Sep; 44(5):783-8. PubMed ID: 14587660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.